This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOAbout ABRYSVOStudy Design & Efficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOResourcesResourcesMaternal RSV Vaccine PlannerHealth Plan CoverageRequest A RepEventsMaterialsVideos
Prescribing InformationIndications AdultPatient Site
RSV is the leading cause of hospitalizations of infants1Infants under 6 months of age are at highest risk of RSV hospitalization

RSV-associated hospitalization rates in infants (0-6 months)2: Cumulative data from 2016-2020

 Despite the risk of hospitalization due to RSV, 44% of infants did not receive any form of RSV protection last season5*With ABRYSVO®, a pregnant individual's immune system produces protective antibodies, which are naturally passed to the infant6

Administer ABRYSVO to your eligible pregnant patient at 32 weeks and 0 days' through 36 weeks and 6 days' gestational age1,7

Your pregnant patient's immune system produces antibodies, which are passed through the placenta to the fetus7

The baby is born with maternal antibodies, which help protect against RSV from birth through 6 months7

Administering ABRYSVO to your eligible pregnant patient may mean one less shot for their baby after birth8†RSV is a common virus that is particularly dangerous for infants9

Transmitted from person to person via respiratory droplets9

RSV can infect the airways of an individual9
Prevention is important. Treatment options are limited to supportive care9
Transmitted from person to person via respiratory droplets2

RSV can infect the airways of an individual2


Prevention is important. Treatment options are limited to supportive care2

Transmitted from person to person via respiratory droplets9

RSV can infect the airways of an individual9

Prevention is important. Treatment options are limited to supportive care9

ReferencesBased on a CDC internet survey including 866 recently pregnant women that reported on receipt of the maternal RSV vaccine or of their infant receiving an RSV immunization after birth during the 2023-2024 season.5Either ABRYSVO or nirsevimab is recommended to prevent severe RSV-LRTD in infants, but both are not needed for most infants. If a pregnant individual is vaccinated with ABRYSVO greater than 14 days before the infant is born, nirsevimab may not be needed, except in specific circumstances.8RSV=respiratory syncytial virus; RSV-LRTD=respiratory syncytial virus-associated lower respiratory tract disease. Maternal RSV Vaccine Planner

For eligible patients, this tool estimates the ABRYSVO vaccination window based upon estimated pregnancy due date, season, and location, consistent with the approved ABRYSVO indication and CDC recommendation.

 View the Planner LoadingInsurance coverage

Learn more about coverage for ABRYSVO for eligible pregnant patients.

Explore NowLoadingStock ABRYSVO

Make ABRYSVO available to your eligible patients by placing an order today.

 Order Now Loading View resourcesDiscover helpful ABRYSVO resources, videos, and patient materials. Get AccessLoading
Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading

References:

Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122.Curns AT, Rha B, Lively JY, et al. Respiratory syncytial virus-associated hospitalizations among children <5 years old: 2016 to 2020. Pediatrics. 2024;153(3):e2023062574.Fauroux B, Simões EAF, Checchia PA, et al. The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther. 2017;6(2):173-197.Homaira N, Briggs N, Oei JL, et al. Association of age at first severe respiratory syncytial virus disease with subsequent risk of severe asthma: a population-based cohort study. J Infect Dis. 2019;220(4):550-556.Razzaghi H, Garacci E, Kahn KE, et al. Maternal respiratory syncytial virus vaccination and receipt of respiratory syncytial virus antibody (nirsevimab) by infants aged <8 months — United States, April 2024. MMWR Morb Mortal Wkly Rep. 2024;73(38):837-843. Centers for Disease Control and Prevention. Immunizations to protect infants. Updated August 18, 2025. Accessed October 23, 2025. https://www.cdc.gov/rsv/vaccines/protect-infants.htmlABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; July 2025.Centers for Disease Control and Prevention. RSV immunization guidance for infants and young children. Updated August 18, 2025. Accessed October 23, 2025. https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.htmlJain H, Schweitzer JW, Justice NA. Respiratory syncytial virus infection in children. Updated June 23, 2023. Accessed October 23, 2025. https://www.ncbi.nlm.nih.gov/books/NBK459215/

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-2565
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)  
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)  
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO. IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerProBy clicking Go to VaxAssist.com, you will be redirected to VaxAssist by Pfizer, where your patients can check eligibility and vaccine options. For additional information on ABRYSVO, please see Important Safety Information.